Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer

Cancer

Volumn 116, Issue 3, 2010, Pages 766-774

  De La Cruz, Maxine ^a   Hui, David ^a   Parsons, Henrique A ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fatigue; Neoplasms; Nocebo; Placebo

Indexed keywords

DONEPEZIL; METHYLPHENIDATE; PLACEBO;

ADVANCED CANCER; ANOREXIA; ANXIETY; APPETITE; ARTICLE; BEHAVIOR CHANGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PLACEBO EFFECT; PRIORITY JOURNAL; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SLEEP; SLURRED SPEECH; TACHYCARDIA; VERTIGO; WELLBEING;

ADULT; AGED; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 76249105846     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24751     Document Type: Article

References (40)

1. National Comprehensive Cancer Network. Cancer Related Fatigue. Clinical Practice Guidelines in Oncology. Fort Washington, Pa: National Comprehensive Cancer Network; 2007.
2. Bruera E, Neumann C, Brenneis C, Quan H. Frequency of symptom distress and poor prognostic indicators in palliative cancer patients admitted to a tertiary palliative care unit, hospices, and acute care hospitals. J Palliat Care. 2000;16:16-21.
3. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997;34(suppl 2):4-12.
4. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001; 19:3385-3391.
5. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40-50.
6. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park). 1998;12:369-377.
7. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24:2073-2078.
8. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007;25:3475-3481.
9. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain. 2005;115:338-347.
10. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain. 2003;105:17-25.
11. Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F. Response expectancies in placebo analgesia and their clinical relevance. Pain. 2001;93:77-84.
12. Pollo A, Torre E, Lopiano L, et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport. 2002;13:1383-1386.
13. Brown WA. The placebo effect. Sci Am. 1998;278:90-95.
14. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med. 1997;26(pt 1):607-611.
15. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6-9.
16. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(suppl 2):13-19.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
18. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164-2171.
19. Beecher HK. The powerful placebo. JAMA. 1955;159: 1602-6.
20. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594-1602.
21. Colloca L, Benedetti F. How prior experience shapes placebo analgesia. Pain. 2006;124:126-133.
22. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211-218.
23. Linde K, Witt CM, Streng A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007;128:264-271.
24. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry. 2004;61:412-420.
25. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25:10390-10402.
26. Kaptchuk TJ, Kelley JM, Deykin A, et al. Do "placebo responders" exist? Contemp Clin Trials. 2008;29:587-595.
27. Lasagna L, Beecher HK. The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther. 1954;112:356-363.
28. Averbuch M, Katzper M. Gender and the placebo analgesic effect in acute pain. Clin Pharmacol Ther. 2001;70:287-291.
29. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5:e166.
30. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005; 45:232-239.
31. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271:1609-1614.
32. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006;23:923-936.
33. Hyland ME, Whalley B, Geraghty AW. Dispositional predictors of placebo responding: a motivational interpretation of flower essence and gratitude therapy. J Psychosom Res. 2007;62:331-340.
34. Whalley B, Hyland ME, Kirsch I. Consistency of the placebo effect. J Psychosom Res. 2008;64:537-541.
35. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622-627.
36. Shepherd M. The placebo: from specificity to the non-specific and back. Psychol Med. 1993;23:569-578.
37. Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther. 1993;54:578-583.
38. Pogge RC. The toxic placebo. I. Side and toxic effects reported during the administration of placebo medicine. Med Times. 1963;91:773-778.
39. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 1999;83:147-156.
40. Montgomery SA. The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol. 1999;9:271-276.